Harvard UAEM

Our Labs. Our Drugs. Our Responsibility.

Universities Allied for Essential Medicines

UAEM is a 501(c)(3) nonprofit and tax-exempt organization. Our work has been made possible by generous support from the Doris Duke Charitable Foundation, the Ford Foundation, the John M. Lloyd Foundation, the Kaiser Family Foundation, the Moriah Fund, the Open Society Institute, Oxfam America, the Perls Foundation and the contributions of our individual donors.

Our membership consists of chapters at universities on five continents. We draw on the combined strengths of students in undergraduate studies as well as graduate schools of law, medicine, public health, basic and applied sciences, and government.

UAEM is governed by a salaried Executive Director, a volunteer Board of Directors of both professionals and students, and a volunteer Coordinating Committee of students. We are supported by an Advisory Board which includes Dr. Paul Farmer, Nobel laureate in Medicine Sir John Sulston, and experts in law and access to medicines.

   UAEM’s aims are threefold:

  1. To promote access to medicines for people in developing countries by changing norms and practices arounduniversity patenting and licensing
  2. To ensure that university medical research meets the needs of the majority of the world’s population
  3. To empower students to respond to the access and innovation crisis

We encourage supporters to sign on to our mission by endorsing the Philadelphia Consensus Statement. Signatories include nine Nobel Laureates and thirty-three organizations, including Partners in Health.

Our work has been described in news outlets and peer-reviewed journals including Bloomberg News, JAMA, the British Medical Journal, PLoS Medicine, PLoS Neglected Tropical Diseases, Nature Reviews Microbiology, and many others. Find a list of our publications here.  More information may be found on the UAEM website.

Harvard UAEM Mission & Values

Every year, 10 million people die unnecessarily because they lack access to existing medical treatments; high prices and legal barriers are often contributing factors. A further billion people are infected with one or more so-called “neglected” diseases, for which safe and effective treatments have not been developed because the patients are too poor to provide an economic incentive.

In both cases, universities are well-placed to make a difference. University scientists are major contributors to the drug development pipeline. At the same time, universities are commited to advancing the public good.

With this in mind, Universities Allied for Essential Medicines, an interdisciplinary group of university students, aims to enhance the global health impact of our schools’ biomedical research. We advocate for universities to ensure that biomedical end products, such as drugs, developed in campus labs are affordable and accessible in poor countries, and we work to reduce or eliminate barriers to research on neglected diseases.

Read more about UAEM’s work across Canada, the US, and the UK at uaem.org.

Lastly, if this all sounds good to you, we invite you to sign on to our statement of principles.

Comments are closed.